유럽의 규제과학 및 규제과학 인재양성 프로젝트 = European Regulatory Science and Regulatory Science Expert Training Project

다국어 초록 (Multilingual Abstract)

Background: Need for regulatory science is emerging with the development of pharmaceutical industry. It is essential to train regulatory science experts to meet the needs of technology and regulations to evaluate advanced products. Major regulatory science countries are conducting the regulatory science activities and fostering the experts. Methods: Published literature and the relevant website of European Union (EU) were reviewed and criteria were developed. In particular, we focused on in depth descriptions of the Innovative Medicines Initiative program, which was conducted twice. Results: EU is striving to provide funding and training experts for the development of the regulatory science by horizon 2020 and regulatory science to 2025. Innovative medicines initiative (IMI) is a public-private partnership aimed at the development of the pharmaceutical industry, including the regulatory science. IMI education and training projects have provided various education and training course including short-term curriculum and master and doctoral course. The difference between South Korea's regulatory science expert training project in 2021 and the EU's IMI education and training projects is participation of pharmaceutical companies. While the pharmaceutical companies participate in the IMI project to select project topics and form a community, South Korea's project is focused on the Ministry of Food and Drug Safety and universities. Conclusion: Through successful active networks with regulatory party, pharmaceutical companies, and universities, a great innovative advance of regulatory science in South Korea is expected.

참고문헌 (Reference)

1 Gaspar R, "Towards a European strategy for medicines research(2014-2020) : The EUFEPS position paper on Horizon 2020" 47 (47): 979-987, 2012

2 Meyer RJ, "The role of academic medical centers in advancing regulatory science" 95 (95): 471-473, 2014

3 Laverty H, "The innovative medicines initiative-10 years of public-private collaboration" 6 : 275-, 2019

4 Goldman M, "The innovative medicines initiative moves translational immunology forward" 43 (43): 298-302, 2013

5 Goldman M, "The innovative medicines initiative : an engine for regulatory science" 14 (14): 1-2, 2015

6 Goldman M, "The innovative medicines initiative : a European response to the innovation challenge" 91 (91): 418-425, 2012

7 Hines PA, "The European Medicines Agency’s goals for regulatory science to 2025" 18 (18): 403-404, 2019

8 Institute of Medicine, "Strengthening a workforce for innovative regulatory science in therapeutics development: workshop summary" National Academies Press 31-41, 2012

9 "SafeSciMET website"

10 European Medicines Agency, "Road map to 2015"

11 Innovative Medicines Initiative, "Report from the IMI-EMA-FDA regulatory science summit-collaborative research through publicprivate partnership in support to advancing regulatory science"

12 Ministry of Food and Drug Safety, "Regulatory science talent training project (R&D) announcement"

13 Donnelly F, "Regulatory science as a means to respond to EU healthcare challenges and global market meeds" 4 : 21-28, 2016

14 Hines PA, "Regulatory science and innovation programme for Europe(ReScIPE) : A proposed model" 86 (86): 2530-2534, 2020

15 Dance A, "Regulatory science : Researchers in the pipeline" 496 (496): 387-389, 2013

16 Honig P, "Regulation and innovation : Role of regulatory science in facilitating pharmaceutical innovation" 105 (105): 778-781, 2019

17 "PharmaTrain website"

18 Payton A, "On-course(®)portal : a tool for in-service training and career development for biomedical scientists" 18 (18): 803-806, 2013

19 "LifeTrain website"

20 Hardman M, "LifeTrain : towards a European framework for continuing professional development in biomedical sciences" 12 (12): 407-408, 2013

21 Bespalov A, "Introduction to the EQIPD quality system" 10 : e63294-, 2021

22 "Innovative Medicines Initiative website"

23 Spindler P, "Innovation of medical products: The evolution of regulatory science, research, and education" 50 (50): 44-48, 2016

24 "IMI EMTRAIN website"

25 "Horizon 2020" 11 (11): 477-, 2020

26 Bongiovanni S, "Good research practice in non-clinical pharmacology and biomedicine. Handbook of Experimental Pharmacology, vol 257" Springer Open 1-17, 2020

27 Klech H, "European initiative towards quality standards in education and training for discovery, development and use of medicines" 45 (45): 515-520, 2012

28 "Eu2P website"

29 Sakuma I, "Education and training in regulatory science for medical device development" 3155-3158, 2013

30 Kerpel-Fronius S, "Education and training for medicines development, regulation, and clinical research in emerging countries" 6 : 80-, 2015

31 "EQIPD website"

32 European Medicines Agency, "EMA regualtory science to 2025strategic reflection"

33 Payton A, "Course fees and academic ranking : insights from the IMI EMTRAIN on-course® database" 19 (19): 830-833, 2014

34 Silva H, "Core competencies for pharmaceutical physicians and drug development scientists" 4 : 105-, 2013

35 Silva H, "Continuing medical education and professional development in the European Union" 26 (26): 223-233, 2012

36 Duke-NUS medical school, "Center of regulatory excellence"

37 Boeynaems JM, "A European approach to clinical investigator training" 4 : 112-, 2013